The first edition of the clinical practice guidelines for liver cirrhosis was published in 2010,
and the second edition was published in 2015 by the Japanese Society of Gastroenterology …

Primary biliary cholangitis is an autoimmune liver disease that predominantly affects women.
It is characterised by a chronic and destructive, small bile duct, granulomatous lymphocytic …

Background Primary biliary cholangitis is a rare, chronic cholestatic liver disease
characterized by the destruction of interlobular bile ducts, leading to cholestasis and liver …

Background Effective treatments for patients with primary biliary cholangitis are limited.
Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential …

Management of primary or secondary sclerosing cholangitis is challenging. These Clinical
Practice Guidelines have been developed to provide practical guidance on debated topics …

Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIH,
autoimmune hepatitis; ALP, alkaline phosphatase; ASIR, age standardized incidence rate; …

Cholestatic and non-alcoholic fatty liver disease (NAFLD) share several key
pathophysiological mechanisms which can be targeted by novel therapeutic concepts that …

Background & Aims Patients with primary biliary cholangitis (PBC) who have an incomplete
response to ursodeoxycholic acid remain at risk of disease progression. We investigated the …

Hong You1· Xiong Ma2· Cumali Efe3· Guiqiang Wang4· Sook‑Hyang Jeong5· Kazumichi
Abe6· Weijia Duan1· Sha Chen1· Yuanyuan Kong7· Dong Zhang8· Lai Wei9· Fu‑Sheng …

Seladelpar efficacy and safety at 3 months in patients with... : Hepatology Seladelpar
efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a …